🇺🇸 FDA
Patent

US 10323034

Octahydro fused azadecalin glucocorticoid receptor modulators

granted A61PA61P35/00

Quick answer

US patent 10323034 (Octahydro fused azadecalin glucocorticoid receptor modulators) held by Corcept Therapeutics Incorporated expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P35/00